Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Faeth Therapeutics, Inc.NASDAQ: FTH
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $9.18M rose 262.4% year over year, ahead of the +107.0% change in trailing-twelve-month research & development. Sequentially, it fell 48.9% from the prior quarter. Over 3 fiscal years it compounded at -28.2% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +262.4% holds above the trailing-twelve-month pace of +107.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 10.96M USD
- Year-over-year change
- -41.2%
- 4-year CAGR
- -15.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.96M | -41.2% |
| FY2024 | 2024-12-31 | 18.63M | +1.8% |
| FY2023 | 2023-12-31 | 18.3M | -38.1% |
| FY2022 | 2022-12-31 | 29.58M | +36.6% |
| FY2021 | 2021-12-31 | 21.66M | — |
Research & Development vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's LTM Jun 2026 research & development of $31.84M is the lowest of the 10 companies compared; the peer median is $127.65M.
- Its year-over-year change of +107.0% is the highest of 10, against a peer median of +18.2%.
- Over three fiscal years its annual growth of -28.2% compares with a peer median of +7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $270.72M | -4.1% | +2.0% | 2615.7% | |
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
| LTM Mar 2026 | $68M | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $42.44M | -21.4% | +6.5% | — | |
| LTM Jun 2026 | $31.84M | +107.0% | -28.2% | — | |
| Peer median (excluding FTH) | $127.65M | +18.2% | +7.7% | 363.4% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 685K | 1.81M | 571K | 551K | 0 |
| Gross Profit | (685K) | (1.81M) | (571K) | (551K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.66M | 29.58M | 18.3M | 18.63M | 10.96M |
| Selling, General & Admin | 15.14M | 17.73M | 18.77M | 12.49M | 11.33M |
| Operating Expenses | 36.8M | 47.31M | 36.49M | 31.11M | 22.29M |
| Depreciation & Amortization | 685K | 1.81M | 3.68M | 551K | 139K |
| EBITDA | (35.44M) | (46.56M) | (33.39M) | (29.52M) | (20.91M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.48M) | (49.12M) | (37.06M) | (31.66M) | (22.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 800K | 1.78M | 3.62M | 2.55M | 1.24M |
| Interest Expense | 670K | 219K | 144K | 90K | 32K |
| Other Income / Expenses | 688K | 532K | 2.96M | 1.51M | 1.2M |
| Income Before Tax | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| EPS (Diluted) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| Weighted Avg Shares | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
| Weighted Avg Shares (Diluted) | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.